AR and prostate carcinoma: The fact that ERBB2 overexpression increased metastatic potentials specifically in the two androgen-insensitive prostate cancer cell lines (but not in the two androgen-sensitive prostate cancer cell lines) suggests that ERBB2 promotes prostate cancer metastasis by collaborating with androgen/androgen receptor signaling.